CTRI/2012/05/002676招募中3 期
ong-term single-arm open-label study, to assess the safety and tolerability of ACT-293987 in patients with pulmonary arterial hypertension - GRIPHON O
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 670
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients who have completed the double-blind study AC-065A302 as scheduled per protocol (i.e., treated until unblinding of the study), or who have experienced a clinical worsening of PAH (adjudicated by the CEC) during study AC-065A302.
- •Signed informed consent
排除标准
- •Any major violation of protocol AC-065A302.
- •Females who plan to become pregnant during the study, or are breastfeeding.
- •Any known factor or disease that might interfere with treatment compliance, study conduct or interpretation of the results, such as drug or alcohol dependence, or psychiatric disease.
- •Known hypersensitivity to ACT-293987 or any of the excipients.
研究者
相似试验
进行中（未招募）
1 期
Study to evaluate if selexipag is safe for the treatment of pulmonary arterial hypertensioEUCTR2009-014992-31-ATActelion Pharmaceuticals Ltd1,150
进行中（未招募）
1 期
Study to evaluate if selexipag is safe for the treatment of pulmonary arterial hypertensioThe intended indication is Pulmonary Arterial HypertensionMedDRA version: 19.0Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2009-014992-31-DEActelion Pharmaceuticals Ltd1,150
进行中（未招募）
1 期
Study to evaluate if selexipag is safe for the treatment of pulmonary arterial hypertensioThe intended indication is Pulmonary Arterial HypertensionMedDRA version: 18.0Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2009-014992-31-HUActelion Pharmaceuticals Ltd1,150
进行中（未招募）
1 期
Study to evaluate if selexipag is safe for the treatment of pulmonary arterial hypertensioThe intended indication is Pulmonary Arterial HypertensionMedDRA version: 20.0Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2009-014992-31-PLActelion Pharmaceuticals Ltd1,150
进行中（未招募）
1 期
ong-term single-arm open-label study, to assess the safety and tolerability of ACT-293987 in patients with pulmonary arterial hypertension - GRIPHON OEUCTR2009-014992-31-FRActelion Pharmaceuticals Ltd544